SCHEMBL6421787

SCHEMBL6421787

CCCC(=O)Nc1ccc2c(c1)CCCN2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.52
NPC1 O15118 2/20 0.52
PLAU P00749 1/20 0.51
KDM4E B2RXH2 4/20 0.50
MAPT P10636 3/20 0.50
MAPK1 P28482 1/20 0.49
ALDH1A1 P00352 5/20 0.48
HPGD P15428 2/20 0.48
TP53 P04637 3/20 0.48
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
HDAC9 Q9UKV0 1/20 0.46
LMNA P02545 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
THRB P10828 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11404010 0.90 RAB9A (0.52) RAB9ANPC1KDM4EMAPTMAPK1
SCHEMBL3545975 0.83 PLAU (0.50) RAB9ANPC1PLAUKDM4EMAPT
Hydrochloric Acid SCHEMBL3548106 0.82 PLAU (0.49) RAB9ANPC1PLAUKDM4EMAPT
SCHEMBL30464664 0.82 PLAU (0.56) RAB9ANPC1PLAUKDM4EMAPT
SCHEMBL5053574 0.82 PLAU (0.56) RAB9ANPC1PLAUKDM4EMAPT
SCHEMBL7903033 0.81 RAB9A (0.57) RAB9ANPC1PLAUKDM4EMAPT
SCHEMBL691153 0.80 MAPT (0.60) RAB9ANPC1PLAUKDM4EMAPT
SCHEMBL6981447 0.80 NPC1 (0.68) RAB9ANPC1PLAUKDM4EMAPT
SCHEMBL11411975 0.78 RAB9A (0.55) RAB9ANPC1KDM4EMAPTALDH1A1
SCHEMBL20291398 0.76 PLAU (0.53) RAB9ANPC1PLAUKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930104-B2 Heterocyclic derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-16 US disclosed
US-20040157850-A1 Novel heterocyclic derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-08-12 US disclosed
EP-1382598-A1 NOVEL HETEROCYCLIC DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2004-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157850-A1 Novel heterocyclic derivatives APP, BACE1, PSEN1 RAB9A 2333/4885NPC1 207/4885PLAU 2069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.